ScoreWhy is BioMarin Pharmaceutical, Inc. ?
1
Company has a low Debt to Equity ratio (avg) at times
2
Healthy long term growth as Operating profit has grown by an annual rate 60.52%
3
The company has declared Positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 913.97 MM
- NET PROFIT(HY) At USD 450.19 MM has Grown at 90.44%
- RAW MATERIAL COST(Y) Fallen by -10.47% (YoY)
4
With ROE of 12.60%, it has a very expensive valuation with a 1.82 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -24.86%, its profits have risen by 106.7% ; the PEG ratio of the company is 0.1
5
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
6
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -24.86% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to BioMarin Pharmaceutical, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is BioMarin Pharmaceutical, Inc. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
BioMarin Pharmaceutical, Inc.
-22.78%
-0.97
35.96%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
10.90%
EBIT Growth (5y)
60.52%
EBIT to Interest (avg)
11.59
Debt to EBITDA (avg)
0.18
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
0.42
Tax Ratio
22.31%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
3.46%
ROE (avg)
7.17%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.82
EV to EBIT
11.90
EV to EBITDA
10.85
EV to Capital Employed
1.96
EV to Sales
3.30
PEG Ratio
0.14
Dividend Yield
NA
ROCE (Latest)
16.48%
ROE (Latest)
12.60%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 913.97 MM
NET PROFIT(HY)
At USD 450.19 MM has Grown at 90.44%
RAW MATERIAL COST(Y)
Fallen by -10.47% (YoY
CASH AND EQV(HY)
Highest at USD 2,909.96 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -14.31 %
-3What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.47 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.94 times
EPS(Q)
Lowest at USD -0.16
Here's what is working for BioMarin Pharmaceutical, Inc.
Operating Cash Flow
Highest at USD 913.97 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
At USD 450.19 MM has Grown at 90.44%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Cash and Eqv
Highest at USD 2,909.96 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -14.31 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -10.47% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for BioMarin Pharmaceutical, Inc.
EPS
Lowest at USD -0.16
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
Inventory Turnover Ratio
Lowest at 0.47 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 3.94 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
